SKYRIZI® (risankizumab) Gains Approval in Ontario and Alberta for Ulcerative Colitis Treatment
SKYRIZI® (risankizumab), a medication developed by AbbVie, has been approved for inclusion in the public drug formularies of Ontario and Alberta for the treatment of moderately to severely active ulcerative colitis (UC). This development follows positive reimbursement recommendations for both Crohn's disease and ulcerative colitis. SKYRIZI® is a humanized monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. The drug is intended for patients who have not responded adequately to conventional therapies, biologic treatments, or Janus kinase (JAK) inhibitors. The listing in these provinces is part of a broader effort to make SKYRIZI® accessible across Canada, with similar listings already in place in Quebec, Nova Scotia, and Prince Edward Island. 
